Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.

ABSTRACT:

Introduction

Since 2005 the S7B and E14 guidances from ICH and FDA have been in place to assess a potential drug candidate's ability to cause long QT syndrome. To refine these guidelines, the FDA proposed the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, where the assessment of drug effects on cardiac repolarization was one subject of investigation. Within the myocyte validation study, effects of pharmaceutical compounds on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were assessed and this article will focus on the evaluation of the proarrhythmic potential of 23 blinded drugs in four hiPSC-CM cell lines.

Methods

Experiments were performed on the CardioExcyte 96 at different sites. A combined readout of contractility (via impedance)

SUBMITTER: Bot CT 

PROVIDER: S-EPMC6146285 | biostudies-literature | 2018 Sep - Oct

REPOSITORIES: biostudies-literature